A large, multicenter, 3-year extension study assessing efficacy and safety of onabotulinumtoxinA (onabotA) for treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) in patients not adequately managed with an anticholinergic
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary incontinence
- Focus Therapeutic Use
- 26 Dec 2015 New trial record